NCT06227624View on ClinicalTrials.gov

Role of Oral Zinc in Reducing Neonatal Indirect Hyperbilirubinemia

PHASE3CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

June 1, 2019

Study Completion Date

January 1, 2020

Conditions
Neonatal Jaundice
Interventions
DRUG

Oral zinc sulfate and standard phototherapy

study the role of oral zinc sulfate in reducing level of indirect hyperbilirubinemia in neonates if used with standard phototherapy

Trial Locations (1)

32511

National Liver Institute, Shibīn al Kawm

All Listed Sponsors
lead

National Liver Institute, Egypt

OTHER

NCT06227624 - Role of Oral Zinc in Reducing Neonatal Indirect Hyperbilirubinemia | Biotech Hunter | Biotech Hunter